Mr Brendan Reardon

Brendan Reardon’s research focuses on developing algorithms for the clinical interpretation of individual patient molecular data for precision oncology.
Links

ORCID
Publications

Full list of publications see Google Scholar
Recent publications include
[1] S. H. AlDubayan, J. R. Conway, S. Y. Camp, et al. "Detection of
Pathogenic Variants With Germline Genetic Testing Using Deep Learning
vs Standard Methods in Patients With Prostate Cancer and Melanoma".
Eng. In: _JAMA_ 324.19 (Nov. 2020), pp. 1957-1969. ISSN: 1538-3598.
DOI: 10.1001/jama.2020.20457. PMID: 33201204.
[2] J. Bellmunt, J. Kim, B. Reardon, et al. "Genomic Predictors of Good
Outcome, Recurrence, or Progression in High-Grade T1
Non-Muscle-Invasive Bladder Cancer". Eng. In: _Cancer research_ 80.20
(Oct. 2020), pp. 4476-4486. ISSN: 1538-7445. DOI:
10.1158/0008-5472.CAN-20-0977. PMID: 32868381.
[3] S. Y. Camp, E. Kofman, B. Reardon, et al. "Evaluating the molecular
diagnostic yield of joint genotyping-based approach for detecting rare
germline pathogenic and putative loss-of-function variants". Eng. In:
_Genetics in medicine : official journal of the American College of
Medical Genetics_ 23.5 (May. 2021), pp. 918-926. ISSN: 1530-0366. DOI:
10.1038/s41436-020-01074-w. PMID: 33531667.
[4] J. R. Conway, F. Dietlein, A. Taylor-Weiner, et al. "Integrated
molecular drivers coordinate biological and clinical states in
melanoma". Eng. In: _Nature genetics_ 52.12 (Dec. 2020), pp. 1373-1383.
ISSN: 1546-1718. DOI: 10.1038/s41588-020-00739-1. PMID: 33230298.
[5] J. R. Conway, R. Gillani, J. Crowdis, et al. "Somatic structural
variants drive distinct modes of oncogenesis in melanoma". Eng. In:
_The Journal of clinical investigation_ 134.13 (May. 2024). ISSN:
1558-8238. DOI: 10.1172/JCI177270. PMID: 38758740.
[6] C. Gurjao, R. Zhong, K. Haruki, et al. "Discovery and Features of
an Alkylating Signature in Colorectal Cancer". Eng. In: _Cancer
discovery_ 11.10 (Oct. 2021), pp. 2446-2455. ISSN: 2159-8290. DOI:
10.1158/2159-8290.CD-20-1656. PMID: 34140290.
[7] S. H. Han, S. Y. Camp, H. Chu, et al. "Integrative Analysis of
Germline Rare Variants in Clear and Non-clear Cell Renal Cell
Carcinoma". Eng. In: _European urology open science_ 62 (Apr. 2024),
pp. 107-122. ISSN: 2666-1683. DOI: 10.1016/j.euros.2024.02.006. PMID:
38496821.
[8] S. Han, S. Y. Camp, H. Chu, et al. "Integrative Analysis of
Germline Rare Variants in Clear and Non-Clear Cell Renal Cell
Carcinoma". Eng. In: _medRxiv : the preprint server for health
sciences_ (Jan. 2023). DOI: 10.1101/2023.01.18.23284664. PMID:
36712083.
[9] B. M. Huffman, H. Singh, L. R. Ali, et al. "Biomarkers of
pembrolizumab efficacy in advanced anal squamous cell carcinoma:
analysis of a phase II clinical trial and a cohort of long-term
responders". Eng. In: _Journal for immunotherapy of cancer_ 12.1 (Jan.
2024). ISSN: 2051-1426. DOI: 10.1136/jitc-2023-008436. PMID: 38272561.
[10] T. E. Keenan, J. L. Guerriero, R. Barroso-Sousa, et al. "Molecular
correlates of response to eribulin and pembrolizumab in hormone
receptor-positive metastatic breast cancer". Eng. In: _Nature
communications_ 12.1 (Sep. 2021), p. 5563. ISSN: 2041-1723. DOI:
10.1038/s41467-021-25769-z. PMID: 34548479.
[11] N. R. Mahadevan, E. H. Knelson, J. O. Wolff, et al. "Intrinsic
Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular
Plasticity". Eng. In: _Cancer discovery_ 11.8 (Aug. 2021), pp.
1952-1969. ISSN: 2159-8290. DOI: 10.1158/2159-8290.CD-20-0913. PMID:
33707236.
[12] V. McPherson, B. Reardon, A. Bhayankara, et al. "A phase 2 trial
of buparlisib in patients with platinum-resistant metastatic urothelial
carcinoma". Eng. In: _Cancer_ 126.20 (Oct. 2020), pp. 4532-4544. ISSN:
1097-0142. DOI: 10.1002/cncr.33071. PMID: 32767682.
[13] M. Mossanen, F. L. F. Carvalho, V. Muralidhar, et al. "Genomic
Features of Muscle-invasive Bladder Cancer Arising After Prostate
Radiotherapy". Eng. In: _European urology_ 81.5 (May. 2022), pp.
466-473. ISSN: 1873-7560. DOI: 10.1016/j.eururo.2021.12.004. PMID:
34953602.
[14] T. H. Mouhieddine, A. S. Sperling, R. Redd, et al. "Clonal
hematopoiesis is associated with adverse outcomes in multiple myeloma
patients undergoing transplant". Eng. In: _Nature communications_ 11.1
(Jun. 2020), p. 2996. ISSN: 2041-1723. DOI: 10.1038/s41467-020-16805-5.
PMID: 32533060.
[15] B. Reardon, N. D. Moore, N. S. Moore, et al. "Integrating
molecular profiles into clinical frameworks through the Molecular
Oncology Almanac to prospectively guide precision oncology". Eng. In:
_Nature cancer_ 2.10 (Oct. 2021), pp. 1102-1112. ISSN: 2662-1347. DOI:
10.1038/s43018-021-00243-3. PMID: 35121878.
[16] J. M. Rusert, E. F. Juarez, S. Brabetz, et al. "Functional
Precision Medicine Identifies New Therapeutic Candidates for
Medulloblastoma". Eng. In: _Cancer research_ 80.23 (Dec. 2020), pp.
5393-5407. ISSN: 1538-7445. DOI: 10.1158/0008-5472.CAN-20-1655. PMID:
33046443.
[17] J. Schiantarelli, T. Pappa, J. Conway, et al. "Mutational
Footprint of Platinum Chemotherapy in a Secondary Thyroid Cancer". Eng.
In: _JCO precision oncology_ 6 (Aug. 2022), p. e2200183. ISSN:
2473-4284. DOI: 10.1200/PO.22.00183. PMID: 36075011.
[18] K. Sehgal, T. Pappa, K. Shin, et al. "Dual Immune Checkpoint
Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2
Nonrandomized Clinical Trial". Eng. In: _JAMA oncology_ 10.12 (Dec.
2024), pp. 1663-1671. ISSN: 2374-2445. DOI:
10.1001/jamaoncol.2024.4019. PMID: 39446365.
[19] G. Tarantino, C. A. Ricker, A. Wang, et al. "Genomic heterogeneity
and ploidy identify patients with intrinsic resistance to PD-1 blockade
in metastatic melanoma". Eng. In: _Science advances_ 10.48 (Nov. 2024),
p. eadp4670. ISSN: 2375-2548. DOI: 10.1126/sciadv.adp4670. PMID:
39602539.
[20] D. Van Egeren, K. Kohli, J. L. Warner, et al. "Genomic analysis of
early-stage lung cancer reveals a role for TP53 mutations in distant
metastasis". Eng. In: _Scientific reports_ 12.1 (Nov. 2022), p. 19055.
ISSN: 2045-2322. DOI: 10.1038/s41598-022-21448-1. PMID: 36351964.